Evidence map›Paper›PMID 24535496›Full record

ReviewCurrent opinion in pediatrics2014

Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.

Amber M Messier, Robin K Ohls

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. FoxO proteins in the nervous system.Analytical cellular pathology (Amsterdam) · 2015
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amber M MessierDivision of Neonatology, Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico, USA.
Robin K Ohls

Funding

Brain imaging and developmental follow-up of infants treated with erythropoietinR01HD059856 · NICHD · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI OHLS, ROBIN K · 2010 to 2014
$2.2M
NICHD NIH HHS R01 HD059856NICHD NIH HHS R01HD059856
6 · The paper itself

Abstract

purpose of reviewThe use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infants has been studied for over 20 years. Recent investigations have explored the potential neuroprotective effects of ESAs. We review the recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve the neurodevelopmental outcomes in term and preterm infants. RECENT

findingsContinued work using animal models have confirmed the neuroprotective properties of ESAs, including promotion of oligodendrocyte development in the face of neuronal injury. Clinical studies in term and preterm infants have reported the neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in the studies of preterm infants. SUMMARY: ESAs show great promise in preventing and treating brain injury in term and preterm infants.

Indexed as

Infant, PrematureAnimalsChild DevelopmentDarbepoetin alfaDrug Administration ScheduleErythropoietinHematinicsHumansHypoxia-Ischemia, BrainInfant, NewbornNeuroprotective AgentsDarbepoetin alfaErythropoietinHematinicsNeuroprotective Agents

Identifiers

PMID24535496
PMCPMC4504847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.